Literature DB >> 22382934

Age associated differences in prevalence of individual rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome.

D Glintborg1, H Mumm, P Ravn, M Andersen.   

Abstract

Clinical manifestations and metabolic risk factors may differ according to age in patients with polycystic ovary syndrome (PCOS). Therefore, a retrospective trans-sectional study in academic tertiary-care medical center was designed. A cohort of 446 premenopausal, Caucasian women (age range 15-49 years) with PCOS were divided into 4 subgroups according to age: group 1 (15-19 years, n=42), group 2 (20-29 years, n=180), group 3 (30-39 years, n=187), group 4 (40-49 years, n=37) and underwent clinical evaluation (Ferriman-Gallwey score, BMI, waist, blood pressure), hormone analyses (sex hormones, fasting lipids, insulin, glucose), transvaginal ultrasound, oral glucose tolerance tests (OGTT) (n=234), and ACTH tests (n=201). BMI, waist, Ferriman-Gallwey score, blood pressure, and lipid profile were higher in older vs. younger age groups whereas androgen levels were lower. Measures of insulin resistance were unchanged between age groups, but glucose levels were significantly higher in older age groups. Rotterdam criteria: The prevalence of PCO and biochemical hyperandrogenism decreased in the oldest age group whereas clinical hyperandrogenism increased. Young patients are characterized by PCO and biochemical hyperandrogenism, whereas older patients are more obese with more severe hirsutism and more cardiovascular and metabolic risk factors. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382934     DOI: 10.1055/s-0032-1304608

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

1.  Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.

Authors:  Alice Albu; Serban Radian; Simona Fica; Carmen Gabriela Barbu
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

Review 2.  Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome.

Authors:  Dorte Glintborg; Naja Due Kolster; Pernille Ravn; Marianne Skovsager Andersen
Journal:  Biomedicines       Date:  2022-06-20

Review 3.  Longterm management of Polycystic Ovarian Syndrome (PCOS).

Authors:  Gordon W Bates; Richard S Legro
Journal:  Mol Cell Endocrinol       Date:  2012-12-20       Impact factor: 4.102

4.  Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.

Authors:  Dorte Glintborg; Katrine Hass Rubin; Mads Nybo; Bo Abrahamsen; Marianne Andersen
Journal:  Cardiovasc Diabetol       Date:  2018-03-08       Impact factor: 9.951

5.  Higher blood pressure in normal weight women with PCOS compared to controls.

Authors:  Jan Roar Mellembakken; Azita Mahmoudan; Lars Mørkrid; Inger Sundström-Poromaa; Laure Morin-Papunen; Juha S Tapanainen; Terhi T Piltonen; Angelica Lindén Hirschberg; Elisabet Stener-Victorin; Eszter Vanky; Pernille Ravn; Richard Christian Jensen; Marianne Skovsager Andersen; Dorte Glintborg
Journal:  Endocr Connect       Date:  2021-02       Impact factor: 3.335

6.  Age and BMI Adjusted Comparison of Reproductive Hormones in PCOS.

Authors:  Hana Fakhoury; Hani Tamim; Mazen Ferwana; Imran A Siddiqui; Maysoon Adham; Waleed Tamimi
Journal:  J Family Med Prim Care       Date:  2012-07

7.  Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age.

Authors:  Sebastião Freitas de Medeiros; Márcia Marly Winck Yamamoto; Matheus Antônio Souto de Medeiros; Bruna Barcelo Barbosa; José Maria Soares; Edmund Chada Baracat
Journal:  Endocr Connect       Date:  2020-02       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.